Increases in cardiac output can reverse flow deficits from vasospasm independent of blood pressure: a study using xenon computed tomographic measurement of cerebral blood flow.
BACKGROUND
Vasospasm after subarachnoid hemorrhage remains a management challenge. The accepted treatment involves hypertensive, hypervolemic, hemodilution therapy. However, there is variation in the application of this treatment. Most authors increase mean arterial pressure (MAP), which can be associated with significant morbidity. Others increase cardiac output (CO). In this study, we examined the relationship between volume status, CO, and MAP and cerebral blood flow (CBF) in the setting of vasospasm.


METHODS
A xenon blood flow tomography-based system was used to quantitate CBF. Sixteen patients with vasospasm after subarachnoid hemorrhage were treated with hypervolemia, phenylephrine to increase MAP, or dobutamine to increase CO. Direct CBF measurements were obtained before and after treatment. A strength of this study is that only one variable (central venous pressure, MAP, or CO) was manipulated in each patient, and the effect of this change was measured immediately.


RESULTS
With phenylephrine, mean MAP increased from 102.4 to 132.1 mm Hg. In regions of diminished CBF due to vasospasm, mean CBF increased from 19.2 to 33.7 ml/100 g/min. Similarly, dobutamine increased the cardiac index from a mean of 4.1 to 6.0 L/min/m(2) and slightly decreased MAP. CBF increased from a mean of 24.8 to 35.4 ml/100 g/min. Both were statistically significant changes. With hypervolemia, the average central venous pressure increased from a mean of 5.4 to 7.3 cm H(2)O; no changes in mean CBF were noted.


CONCLUSIONS
This article reports the first human study that shows with direct measurements the independent influence of CO in the setting of vasospasm. Increases in CO without changes in MAP can elevate CBF. This finding has immediate clinical application because CO manipulation is much safer than increasing MAP. Because both interventions were equally efficacious, our protocol has been changed to augment CO as a first measure. Induced hypertension is reserved for patients in whom this initial treatment fails.
Joseph
Mathew
M
Department of Neurosurgery, University of Texas Health Science Center, Houston, Texas, USA. dkim7@partners.org
Ziadi
Saleem
S
Nates
Joseph
J
Dannenbaum
Mark
M
Malkoff
Marc
M
D000328:Adult; D000368:Aged; D001794:Blood Pressure / Q000502:physiology*; D002302:Cardiac Output / Q000502:physiology*; D002316:Cardiotonic Agents / Q000627:therapeutic use; D002560:Cerebrovascular Circulation / Q000502:physiology*; D003131:Combined Modality Therapy; D004280:Dobutamine / Q000627:therapeutic use; D005260:Female; D006438:Hemodilution; D006801:Humans; D008297:Male; D008875:Middle Aged; D010656:Phenylephrine / Q000627:therapeutic use; D014057:Tomography, X-Ray Computed; D020301:Vasospasm, Intracranial / Q000000981:diagnostic imaging* / Q000503:physiopathology* / Q000628:therapy; D014978:Xenon
D002316:Cardiotonic Agents; D010656:Phenylephrine; D014978:Xenon; D004280:Dobutamine